11.48
Schlusskurs vom Vortag:
$11.58
Offen:
$11.67
24-Stunden-Volumen:
8.77M
Relative Volume:
1.41
Marktkapitalisierung:
$7.86B
Einnahmen:
$125.68M
Nettoeinkommen (Verlust:
$4.81B
KGV:
2.0319
EPS:
5.65
Netto-Cashflow:
$-781.21M
1W Leistung:
+4.27%
1M Leistung:
+13.89%
6M Leistung:
-1.71%
1J Leistung:
+2.14%
Roivant Sciences Ltd Stock (ROIV) Company Profile
Firmenname
Roivant Sciences Ltd
Sektor
Branche
Telefon
441-295-5950
Adresse
CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11
Vergleichen Sie ROIV mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ROIV
Roivant Sciences Ltd
|
11.48 | 7.86B | 125.68M | 4.81B | -781.21M | 5.65 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
2024-01-05 | Eingeleitet | Piper Sandler | Overweight |
2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
2023-10-17 | Eingeleitet | Guggenheim | Buy |
2023-06-08 | Eingeleitet | BofA Securities | Neutral |
2022-10-27 | Eingeleitet | JP Morgan | Overweight |
2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
2022-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
2021-12-15 | Eingeleitet | Goldman | Buy |
2021-11-08 | Eingeleitet | H.C. Wainwright | Buy |
2021-10-28 | Eingeleitet | Citigroup | Buy |
2021-10-26 | Eingeleitet | Cowen | Outperform |
2021-10-26 | Eingeleitet | Jefferies | Buy |
2021-10-26 | Eingeleitet | Truist | Buy |
Alle ansehen
Roivant Sciences Ltd Aktie (ROIV) Neueste Nachrichten
Roivant Sciences Ltd. (ROIV): Among David Einhorn’s Stock Picks with Huge Upside Potential - Yahoo Finance
Roivant Sciences Ltd. (ROIV): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential - Insider Monkey
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update - ADVFN
Roivant Sciences: Primed For Growth With A De-Risked Pipeline (NASDAQ:ROIV) - Seeking Alpha
Roivant sciences president Eric Venker sells $1.02 million in stock By Investing.com - Investing.com India
Roivant sciences president Eric Venker sells $1.02 million in stock - Investing.com
Roivant Sciences stock holds $18 target, management shuffle - Investing.com Australia
Roivant Sciences stock holds $18 target, management shuffle By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains overweight on Roivant Sciences stock - Investing.com Australia
Immunovant makes leadership changes - MSN
Roivant Tightens Leadership Grip On Immunovant, Narrows Near-Term IMVT-1402 Focus - insights.citeline.com
Cantor Fitzgerald maintains overweight on Roivant Sciences stock By Investing.com - Investing.com South Africa
Immunovant Announces Next Phase Of Growth With Roivant Including Changes To Its Leadership Team And Additional Indications - marketscreener.com
When (ROIV) Moves Investors should Listen - news.stocktradersdaily.com
Is Roivant Sciences Ltd. (ROIV) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? - Yahoo Finance
Roivant Sciences Ltd. (ROIV): Among the Best Low Priced Growth Stocks to Invest In - Insider Monkey
ROIV Factor-Based Stock Analysis - Nasdaq
Immunovant, Roivant slip after trial data for autoimmune disorder therapy - MSN
Knott David M Jr Decreases Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
KLP Kapitalforvaltning AS Invests $918,000 in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
ROIV stock touches 52-week low at $9.96 amid market fluctuations By Investing.com - Investing.com South Africa
ROIV stock touches 52-week low at $9.96 amid market fluctuations - Investing.com Australia
Is Roivant Sciences (ROIV) the Best Mid Cap Biotech Stock to Buy? - Insider Monkey
Loomis Sayles & Co. L P Has $43.43 Million Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 315,522 Shares of Stock - MarketBeat
Is Roivant Sciences Ltd. (NASDAQ:ROIV) One of The Best Stocks to Buy According to Billionaire David Einhorn? - Insider Monkey
Roivant Sciences president Eric Venker sells shares worth $8.19 million - Investing.com
(ROIV) Trading Advice - news.stocktradersdaily.com
Roivant Sciences finalizes consulting agreement with former officer - Investing.com India
Roivant Phase III Batoclimab Trial Is Positive, But No Filing Planned - insights.citeline.com
Roivant Sciences Says Phase 3 MG Study Meets Primary Endpoint -March 19, 2025 at 08:24 am EDT - Marketscreener.com
Roivant Sciences Announces Positive Results for Batoclimab Studies - TipRanks
Critical Clinical Data Coming: Roivant's Dual Breakthrough Results in MG and CIDP Studies - Stock Titan
(ROIV) Trading Signals - Stock Traders Daily
Wall Street Analysts Believe Montes Archimedes Acquisition (ROIV) Could Rally 60%: Here's is How to Trade - Nasdaq
Roivant at Leerink’s Conference: Strategic Insights and Developments By Investing.com - Investing.com Australia
Does Roivant (ROIV) Offer an Attractive Risk Reward Opportunity? - Insider Monkey
Genevant and Arbutus initiate patent lawsuit against Moderna - The Pharma Letter
10 Cash-Rich Mid Cap Stocks To Buy Now - Insider Monkey
Roivant Sciences Ltd. (ROIV): Among the Cash-Rich Mid Cap Stocks to Buy Now - Insider Monkey
Genevant Sciences and Arbutus Biopharma Initiate - GlobeNewswire
Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Bought by New York State Common Retirement Fund - Defense World
Finanzdaten der Roivant Sciences Ltd-Aktie (ROIV)
Umsatz
Nettogewinn
Free Cashflow
ENV
Roivant Sciences Ltd-Aktie (ROIV) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Venker Eric | President & COO |
Apr 21 '25 |
Sale |
10.22 |
100,000 |
1,022,000 |
1,116,345 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):